Search research articles
Contact Us
Filters
Showing results (111-120 of 146) with videos related to
Page
of 15
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 18, 2013
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation
Kosuke Tanaka, Akito Hata, Reiko Kaji, et al.
The Lancet. Oncology
|
October 13, 2025
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study
Akito Hata, Taira Ninomaru, Hideaki Okada, et al.
Cancer Chemotherapy and Pharmacology
|
March 11, 2017
Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003)
Akito Hata, Nobuyuki Katakami, Yoshihiro Hattori, et al.
Cancer Science
|
October 27, 2021
Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L
Shinya Sakata, Kohei Otsubo, Hisako Yoshida, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 20, 2013
Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma
Daichi Fujimoto, Keisuke Tomii, Takehiro Otoshi, et al.
Clinical Lung Cancer
|
June 21, 2023
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial
Kimio Yonesaka, Hidetoshi Hayashi, Atsushi Nakamura, et al.
Clinical and Translational Radiation Oncology
|
September 6, 2022
The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study
Yuichiro Takeda, Yusaku Kusaba, Yoko Tsukita, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 11, 2025
Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L)
Akira Hamada, Junichi Soh, Akito Hata, et al.
Clinical Lung Cancer
|
May 26, 2021
Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L)
Akira Hamada, Junichi Soh, Akito Hata, et al.
Journal for Immunotherapy of Cancer
|
February 15, 2024
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer
Ryota Shibaki, Daichi Fujimoto, Tsukasa Nozawa, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 146) with videos related to
Sort By:
Page
of 15
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 18, 2013
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation
Kosuke Tanaka, Akito Hata, Reiko Kaji, et al.
The Lancet. Oncology
|
October 13, 2025
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study
Akito Hata, Taira Ninomaru, Hideaki Okada, et al.
Cancer Chemotherapy and Pharmacology
|
March 11, 2017
Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003)
Akito Hata, Nobuyuki Katakami, Yoshihiro Hattori, et al.
Cancer Science
|
October 27, 2021
Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L
Shinya Sakata, Kohei Otsubo, Hisako Yoshida, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 20, 2013
Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma
Daichi Fujimoto, Keisuke Tomii, Takehiro Otoshi, et al.
Clinical Lung Cancer
|
June 21, 2023
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial
Kimio Yonesaka, Hidetoshi Hayashi, Atsushi Nakamura, et al.
Clinical and Translational Radiation Oncology
|
September 6, 2022
The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study
Yuichiro Takeda, Yusaku Kusaba, Yoko Tsukita, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 11, 2025
Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L)
Akira Hamada, Junichi Soh, Akito Hata, et al.
Clinical Lung Cancer
|
May 26, 2021
Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L)
Akira Hamada, Junichi Soh, Akito Hata, et al.
Journal for Immunotherapy of Cancer
|
February 15, 2024
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer
Ryota Shibaki, Daichi Fujimoto, Tsukasa Nozawa, et al.
Page
of 15